Truxima (rituximab-abbs) / Nippon Kayaku, Servier, Celltrion, Mundipharma, Teva, Indukern  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
NCT04268277: Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Recruiting
N/A
56
Europe
Rituximab, Truxima, Pembrolizumab, Keytruda
University of Ulm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Merck Sharp & Dohme LLC, Celltrion Healthcare Co., LTD
Marginal Zone Lymphoma
04/29
04/29

Download Options